STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
Oculis (OCS) has announced the filing of notifications regarding annual equity incentive awards granted to its board directors. The notifications specifically pertain to transactions by T Rosenberg, C Ackermann, A Khanani, and R Warner as part of the June 2025 Board of Directors grant program. These disclosures are standard regulatory filings required for transactions by persons discharging managerial responsibilities within the company.
Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

ZUG, Switzerland, June 09, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to the annual equity incentive awards granted to directors of the Company.

Attachments


FAQ

What type of transactions did Oculis (OCS) disclose in June 2025?

Oculis disclosed notifications regarding annual equity incentive awards granted to its board directors T Rosenberg, C Ackermann, A Khanani, and R Warner.

Who are the Oculis (OCS) board members receiving equity incentive awards in June 2025?

The board members receiving equity incentive awards are T Rosenberg, C Ackermann, A Khanani, and R Warner.

What is the purpose of Oculis (OCS) managers' transaction notifications?

These notifications are regulatory requirements to disclose transactions by persons discharging managerial responsibilities, specifically regarding their annual equity incentive awards.

When were the Oculis (OCS) board director grants issued?

The board director grants were issued in June 2025 as part of the company's annual equity incentive award program.
Oculis Holding

NASDAQ:OCS

OCS Rankings

OCS Latest News

OCS Latest SEC Filings

OCS Stock Data

1.09B
48.60M
6.31%
31.25%
0.02%
Biotechnology
Healthcare
Link
Switzerland
Zug